Key result
This review discusses the RE-LY, ROCKET AF, and ARISTOTLE trials comparing dabigatran, rivaroxaban, and apixaban with warfarin for stroke prevention in nonvalvular atrial fibrillation.
Why the study?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban) improve efficacy and safety for stroke prevention compared to warfarin in patients with nonvalvular atrial fibrillation?
Do new oral anticoagulants (dabigatran, rivaroxaban, apixaban) improve efficacy and safety for stroke prevention compared to warfarin in patients with nonvalvular atrial fibrillation?
This review summarizes the RE-LY, ROCKET AF, and ARISTOTLE trials, comparing the efficacy and safety of dabigatran, rivaroxaban, and apixaban versus warfarin for stroke prevention in nonvalvular atrial fibrillation.
May guide NOAC selection in nonvalvular AF; leaves open head-to-head comparisons and long-term outcomes.
Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa - rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF.
No takes yet. Share an insight, caveat, or question.
Tendera et al. (2012) conducted a review in nonvalvular atrial fibrillation. dabigatran, rivaroxaban, and apixaban vs. warfarin was evaluated. This review discusses the RE-LY, ROCKET AF, and ARISTOTLE trials comparing dabigatran, rivaroxaban, and apixaban with warfarin for stroke prevention in nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: